Imfinzi® (durvalumab) for Lung and Biliary Tract Cancers

What Imfinzi® Is and How It Works

Imfinzi® (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody used to treat certain cancers. It is approved for unresectable stage 3 non-small cell lung cancer after chemoradiation, extensive-stage small cell lung cancer with chemotherapy, and biliary tract cancers with gemcitabine and cisplatin. It is given by intravenous infusion on a repeating schedule. If you are comparing options or planning care, you may be looking at imfinzi price alongside dosing and access.

Durvalumab helps your immune system recognize and attack cancer cells by blocking the PD-L1 pathway. Fixed dosing allows 1500 mg infusions at set intervals in many adults. Youdrugstore is a licensed Canadian pharmacy in Manitoba. Our pharmacists review prescriptions before dispensing and support your order. We offer brand and generic medicines at Canadian prices, and our team is available by chat during posted office hours. We source from licensed, vetted partner pharmacies worldwide to supply authentic brands across a broad selection at affordable pricing.

Dosage and Usage

Follow your oncologist’s plan and the product monograph. Typical regimens include:

• Unresectable stage 3 NSCLC: 10 mg/kg every 2 weeks or 1500 mg every 4 weeks for up to 12 months, after chemoradiation.
• Extensive-stage SCLC: 1500 mg every 3 weeks with etoposide and platinum for 4 cycles, then 1500 mg every 4 weeks until progression or unacceptable toxicity.
• Biliary tract cancer: 1500 mg day 1 every 3 weeks with gemcitabine and cisplatin for 8 cycles, then 1500 mg every 4 weeks as maintenance.
• Infusion: Administer as an IV infusion over about 60 minutes.

Missed infusion:

• If an infusion is missed, contact the treating clinic to reschedule as soon as possible.

Storage and transport (for clinic or pharmacy handling):

• Store vials refrigerated at 2–8 °C in the original carton; protect from light.
• Do not freeze or shake.
• For travel to clinic, keep cold with gel packs in an insulated container if instructed by your provider or clinic.

Ask your care team about premedication for infusion reactions and lab monitoring. Do not change the durvalumab dose or schedule without medical guidance.

Benefits and Savings

Durvalumab treatment can extend progression-free survival in unresectable stage 3 NSCLC after chemoradiation and helps improve outcomes when combined with chemotherapy in extensive-stage SCLC and biliary tract cancers. Fixed 1500 mg dosing may reduce clinic visits compared with weight-based schedules, when appropriate. Many patients value predictable cycles.

Ordering through Youdrugstore helps you compare imfinzi cost, including imfinzi cost per month, to typical US pricing. Savings often reach 60–80% versus US pharmacy prices. Our team offers friendly support and can help you plan multi-month shipments where appropriate.

Side Effects and Safety

Common effects include tiredness, cough, shortness of breath, decreased appetite, nausea, constipation, diarrhea, abdominal pain, rash, and itching. Infusion-related reactions can occur. Most effects are mild to moderate, but close monitoring is standard.

• Immune-related events: pneumonitis, colitis, hepatitis, endocrinopathies (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes), nephritis, severe skin reactions.
• Other serious events: myocarditis, neuropathies, ocular inflammation, severe infusion reactions.
• Lab monitoring: liver enzymes, thyroid function, renal function, and glucose as indicated.
• Pregnancy and lactation: Can harm an unborn baby. Use effective contraception during treatment and for a period after the last dose as directed. Breastfeeding is not recommended during treatment.

Report new or worsening cough, chest pain, diarrhea, jaundice, severe fatigue, confusion, vision changes, or symptoms of hormone imbalance to the care team immediately. Your prescriber may pause, adjust, or stop therapy if serious reactions appear.

Onset Time

Checkpoint inhibitors do not work like traditional chemotherapy. Some patients notice changes within weeks, but responses often take longer. Consolidation therapy benefits in unresectable stage 3 NSCLC emerged over months in clinical studies. Clinicians monitor response with imaging and symptoms at regular intervals and adjust care accordingly.

Compare With Alternatives

Durvalumab in lung cancer is one option among immunotherapies and targeted agents. Other PD-1/PD-L1 inhibitors include pembrolizumab and atezolizumab. A different PD-L1 inhibitor, Bavencio® (avelumab), is used for select cancers and shares class features but differs in indications and dosing.

Targeted therapies treat tumors with specific mutations. For EGFR-mutated NSCLC, Tagrisso® (osimertinib) is often used in defined settings. These medicines work differently from durvalumab and require mutation testing. Choice depends on tumor type, stage, biomarkers, prior therapy, and tolerability.

Your oncology team will compare risks, benefits, and goals of care before recommending an approach. Ask about durvalumab non small cell lung cancer uses versus other options if your tumor has actionable biomarkers.

Combination Therapy

Durvalumab small cell lung cancer treatment pairs durvalumab with etoposide and a platinum agent for first-line extensive-stage disease. For biliary tract cancers, durvalumab in cholangiocarcinoma and related biliary tumors is given with gemcitabine and cisplatin. In unresectable stage 3 NSCLC, durvalumab follows concurrent chemoradiation as consolidation.

Some settings use durvalumab with other immunotherapies under specific protocols. Always follow the regimen and duration your oncologist prescribes.

Patient Suitability and Cost-Saving Tips

Candidates often include adults with unresectable stage 3 lung cancer after chemoradiation, extensive-stage small cell lung cancer, or biliary tract cancers when part of a combination plan. Tumor biomarkers, performance status, autoimmune history, organ function, and prior therapy guide suitability and the durvalumab dose schedule.

To manage costs, compare durvalumab cost and durvalumab price across strengths. Clinics often order 120 mg/2.4 mL and 500 mg/10 mL vials. Ask your clinic which vial sizes fit your plan to help reduce waste. Some patients track imfinzi 500mg price or durvalumab 500 mg price when budgeting.

You can request reorder reminders and discuss multi-month shipments to lower per-month costs when stable on therapy. Explore education on Lung Cancer and broader Cancer topics. For related reading on managing monoclonal therapy effects, see our article on Common Darzalex Side Effects And Tips To Manage Them. To learn how targeted agents differ from immunotherapy, review Understanding Calquence Medication For Cancer Treatment.

Pricing terms patients ask about include imfinzi annual cost and durvalumab cost per dose. These vary by regimen, vial mix, and duration. Your clinic can estimate durvalumab 1500 mg needs for each cycle.

Authoritative Sources

For full details, review the manufacturer’s information on Imfinzi official site, the Health Canada listing in the Drug Product Database, and the FDA durvalumab Prescribing Information.

Youdrugstore is ready to help with ordering, storage guidance, and paperwork. Our pharmacists review prescriptions and support your questions, and our team ships with prompt, express, cold-chain shipping to maintain product integrity.

This information is educational and does not replace advice from your oncology team. Durvalumab has serious risks and requires ongoing monitoring. Product availability, indications, and packaging may vary by country. A valid prescription is required.